Table 4.
Brain and plasma pharmacokinetic parameters of thymoquinone loaded PLGA nanoparticles after intravenous and intranasal delivery.
| Formulation | Organ/tissue | Peak plasma conc. (C max) (ng/mL) |
Time peak plasma conc. (T max) (h) |
Half-life (T
1/2) (h) |
Rate of elimination (K e) (h−1) |
AUC0–72 h
(ng mL−1 h) |
AUC0–∞
(ng mL−1 h) |
|---|---|---|---|---|---|---|---|
| TQ-PLGA NPs (i.v.) | Brain | 390.61 ± 54.44 | 8 | 18.11 ± 1.97 | 0.010 ± 0.003 | 11204.3 ± 3211.6 | 20296.3 ± 3265.6 |
| Plasma | 15897.67 ± 3443.52 | — | 62.34 ± 7.04 | 0.038 ± 0.004 | 312654.2 ± 6542.6 | 351453.2 ± 14915.1 | |
|
| |||||||
| TQ-PLGA NPs (i.n.) | Brain | 996.43 ± 119.36 | 12 | 118.23 ± 3.97 | 0.005 ± 0.000 | 33771.2 ± 994.5 | 98675.6 ± 8157.1 |
| Plasma | 3465.33 ± 664.16 | 4 | 194.24 ± 9.87 | 0.003 ± 0.000 | 142315.1 ± 33217.3 | 359773.4 ± 44132.3 | |
N = 3; data represent mean ± SEM.